Why Longevity Medicine Still Fails Women and What Needs to Change
Dr Poonam Desai argues that personalized medicine rings hollow while clinical frameworks still use male biology as the default standard.
Summary
Longevity medicine claims to personalize care, but its foundations were built on research that largely excluded women until 1993. Dr Poonam Desai, a double board-certified physician in Lifestyle and Precision Medicine, argues that biomarker ranges, dosing protocols, and treatment assumptions calibrated on male physiology continue to create dangerous blind spots for women today. Speaking ahead of The Longevity Show in London, Desai calls for sex-disaggregated data, updated clinical protocols, and equitable access to preventive care. She also highlights that men suffer under cultural norms discouraging preventive engagement. The core message: longevity cannot be democratized while large populations are assessed against reference points never designed for them.
Detailed Summary
Modern longevity medicine markets itself on precision and personalization, but a foundational problem persists: the clinical frameworks underlying most of healthcare were built using male subjects as the biological default. Dr Poonam Desai, founder of Longevity Place and HER Longevity, is drawing attention to how this historical bias continues to shape health outcomes for both women and men in ways the field has yet to fully reckon with.
Until 1993, women were largely excluded from clinical trials in the United States. That exclusion means decades of dosing guidelines, biomarker reference ranges, and diagnostic criteria were calibrated on male physiology. Desai argues the consequences are not historical footnotes — they are active clinical liabilities. Women are still being evaluated against standards that were never designed with their biology in mind, contributing to missed diagnoses and suboptimal treatment across the lifespan.
The conversation extends beyond women's health. Men, Desai notes, are poorly served by cultural assumptions that frame stoicism as strength and discourage preventive care. The result is what she calls an equality in dysfunction — different blind spots for different sexes, but the same systemic failure underlying both.
Desai's proposed remedy is structural. She calls for sex-disaggregated data to become standard practice in research and clinical reporting, and for menopause, andropause, and sex-specific cardiovascular and metabolic risk to be treated as core longevity concerns rather than niche specialties. The framing shifts longevity from elite optimization toward a genuine public health mandate.
The article is primarily a preview of a panel discussion at The Longevity Show in London and does not present new research data. Its value lies in surfacing an underexamined systemic issue within longevity medicine. Readers should note that while the policy arguments are well-grounded, specific clinical recommendations require verification against current peer-reviewed evidence and individual consultation.
Key Findings
- Women were excluded from most US clinical trials until 1993, leaving dosing and biomarker standards calibrated on male physiology.
- Sex-disaggregated data in research and clinical practice is essential for accurate diagnosis and treatment across biological sexes.
- Men face longevity risks from cultural norms discouraging preventive care and early health intervention.
- Menopause and andropause should be treated as core longevity topics, not niche or ancillary concerns.
- Equitable access to evidence-based preventive care is described as foundational to any meaningful longevity advance.
Methodology
This is a news feature and interview preview tied to an industry conference, not a peer-reviewed research summary. The source, Longevity.Technology, is a specialist trade publication with reasonable credibility in the longevity sector. Evidence cited is historical and policy-based rather than drawn from new primary research.
Study Limitations
The article previews a conference panel and contains no new clinical data or study results to evaluate. Claims about research exclusion and protocol bias, while well-documented historically, are not cited to specific sources within this piece. Readers should consult primary literature and current clinical guidelines before making health decisions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.